Brainstorm Cell Therapeut... (BCLI)
Company Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases.
The company has a partnership with Catalent for manufacturing NurOwn.
The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004.
Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Oct 7, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Chaim Lebovits |
Contact Details
Address: 1325 Avenue of Americas New York City, New York United States | |
| Website | https://www.brainstorm-cell.com |
Stock Details
| Ticker Symbol | BCLI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001137883 |
| CUSIP Number | 10501E201 |
| ISIN Number | US10501E3009 |
| Employer ID | 20-7273918 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chaim Lebovits | President & Chief Executive Officer |
| Dr. Hartoun Hartounian Ph.D. | Executive Vice President & Chief Operating Officer |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor |
| Dr. Ibrahim Dagher M.D. | Executive Vice President & Chief Medical Officer |
| Dr. Netta Blondheim-Shraga Ph.D. | Senior Vice President of Research and Development |
| Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | S-3 | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 16, 2025 | ARS | Filing |
| May 16, 2025 | DEFA14A | Filing |
| May 16, 2025 | DEF 14A | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |